Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPA-CKD: Empagliflozin in Veterans With Non-diabetic CKD
NCT07060417Phase 2Not yet recruiting
- Sponsor
- VA Office of Research & Development
- Start
- Oct 2026
- Primary completion
- Mar 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of empagliflozin in chronic kidney disease (CKD), sponsored by VA Office of Research & Development. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
empagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT07060417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07060417.